Skandinaviska Enskilda Banken AB publ Purchases 16,849 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Skandinaviska Enskilda Banken AB increased its stake in United Therapeutics Corporation by 20.1%, now holding 100,854 shares valued at approximately $31 million.
• United Therapeutics reported a net margin of 40.44% and a quarterly revenue of $794.40 million, surpassing analysts' expectations.
• Several firms downgraded United Therapeutics' stock rating recently, impacting its price targets, with Wall Street Zen lowering it from "strong-buy" to "buy."

Skandinaviska Enskilda Banken AB publ increased its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 20.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 100,854 shares of the biotechnology company's stock after acquiring an additional 16,849 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.22% of United Therapeutics worth $31,090,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of UTHR. Dunhill Financial LLC boosted its position in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares during the period. Sound Income Strategies LLC acquired a new stake in shares of United Therapeutics in the first quarter worth $49,000. State of Wyoming acquired a new stake in shares of United Therapeutics in the fourth quarter worth $62,000. Curat Global LLC acquired a new stake in shares of United Therapeutics in the first quarter worth $63,000. Finally, Natixis acquired a new stake in shares of United Therapeutics in the fourth quarter worth $85,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the subject of a number of research reports. Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. UBS Group dropped their price objective on United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. JPMorgan Chase & Co. lowered their price target on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 8th. Finally, Cantor Fitzgerald initiated coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $383.08.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the sale, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the sale, the director owned 4,883 shares of the company's stock, valued at $1,416,021.17. The trade was a 11.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,681 shares of company stock worth $24,628,589 in the last quarter. 10.30% of the stock is owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR traded down $7.45 on Wednesday, hitting $290.11. The company's stock had a trading volume of 408,313 shares, compared to its average volume of 490,703. The company has a market capitalization of $13.09 billion, a PE ratio of 11.57, a PEG ratio of 6.50 and a beta of 0.53. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The company has a 50 day moving average price of $299.63 and a 200 day moving average price of $314.91.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The firm had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. During the same period in the prior year, the company posted $5.85 EPS. The firm's quarterly revenue was up 11.7% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.